The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
Clearmind develops novel psychedelic medicine based treatments to solve widespread, yet underserved health problems. With solid medical management and IP-protected treatments, the company aims to better the lives of millions of people.
The Issuer is in the business of cannabis cultivation, production and dispensaries. The Issuer also has a patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency.
Cognetivity Neurosciences Ltd. is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
CordovaCann Corp. (the “Company” or “CordovaCann”) is a Canadian-domiciled company focused on building a leading, diversified cannabis products business across multiple jurisdictions including Canada and the United States. CordovaCann primarily provides services and investment capital to the processing, production and retail vertical markets of the cannabis industry.
Core One Labs Inc. is a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.
Craftport Cannabis is a licensed producer of medical dried cannabis at its facility in Peachland, British Columbia. Through its 100-per-cent-owned subsidiary, Potanicals Green Growers Inc. ("Potanicals"), Craftport Cannabis received a production and cultivation license in October 2017 and a sales license from Health Canada in July 2019. The Health Canada sales license allows Craftport Cannabis to supply and sell finished cannabis products to provincial governments throughout Canada and through Canada's distribution and retail supply chain. Craftport Cannabis is providing recreational and medical dried cannabis, and will be providing capsules and other forms of cannabis products . As part of its expansion strategy Craftport Cannabis through its wholly-owned subsidiary and licensed producer Potanicals , has received its second cultivation license, effectively November 29, 2019, from Health Canada for the Company's joint venture greenhouse operations located in Pitt Meadows, BC.
Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco Labs is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco Labs’ national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry.
(Note: In addition to the 319,742,627 Subordinate Voting Shares that are issued and outstanding, there are 116,369,118 Subordinate Voting Shares reserved for issuance pursuant to the redemption and conversion rights attached to: (i) the outstanding Proportionate Voting Shares of Cresco Labs Inc. that are not listed, and (ii) certain outstanding securities of Cresco Labs, LLC, which is a subsidiary of Cresco Labs, Inc. The total number of equity shares assuming all are converted into the listed class would be 436,111,745.)
Curaleaf Holdings, Inc., its subsidiaries and managed entities are directly engaged in the manufacture, possession, use, sale or distribution of cannabis and/or hold licenses in the adult-use and/or medicinal cannabis marketplace in the States of Arizona, Connecticut, Florida, Maine, Maryland, Massachusetts, Nevada, New Jersey, New York and Oregon.
Investor Note: In addition to the 633,995,666 Subordinate Voting Shares that are listed and trading, there are 93,970,705 shares reserved specifically for issuance pursuant to the conversion rights attached to the Multiple Voting Shares that are issued and outstanding but not listed. The total number of issued shares assuming all Multiple Voting Shares are converted into the listed class would be 727,966,371.
Defence Therapeutics Inc. is a biotechnology company engaged in the business of research and development, focusing on enhancing delivery of tumor-/ and infectious disease-specific therapeutics. The principal business carried on is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases.
Delota Corp. is an established vape and cannabis retailer that curates and sells vape and nicotine-related products, other smoking cessation products, cannabis products, and accessories where regulations permit. The Company currently operates 28 brick-and-mortar specialty vape stores in Ontario under the 180 Smoke Vape Store banner name, a leading Canada-wide specialty vape e-commerce platform (www.180smoke.ca), and five licenced dispensaries under the Offside Cannabis banner name in Ontario.
